Document is current
Any future updates will be listed below
-
Authors
Kawamoto, Yasuyuki https://orcid.org/0000-0002-7706-0015
Sawada, Kentaro
Harada, Kazuaki
Motoo, Iori
Ando, Takayuki
Sogabe, Susumu
Kobayashi, Yoshimitsu
Dazai, Masayoshi
Nakamura, Michio
Hatanaka, Kazuteru
Ishiguro, Atsushi
Sato, Atsushi
Nakano, Shintaro
Shindo, Yoshiaki
Hosokawa, Ayumu
Ito, Ken
Yoshikawa, Ayumu
Ueda, Akira
Iuchi, Kayoko
Yokota, Isao
Yuki, Satoshi
Komatsu, Yoshito
-
Funding
Funding for this research was provided by:
Nipro (No grant number)
- License Information
-
More Information
Article History
Received: 22 December 2025
Accepted: 16 April 2026
First Online: 4 May 2026
Declarations
:
: Yasuyuki Kawamoto: Eli Lilly Japan and Taiho Pharma (H); Kentaro Sawada: Ono Pharma and Taiho Pharma (H); Kazuaki Harada: Eli Lilly Japan and Nippon Kayaku (H); Michio Nakamura: Eli Lilly Japan, Daiichi Sankyo, Taiho Pharma and Bristol-Myers Squibb (H); Ayumu Hosokawa: Eli Lilly Japan and Nippon Kayaku (H); Satoshi Yuki: Eli Lilly Japan (H); Yoshito Komatsu: Eli Lilly Japan, Taiho Pharma, Daiichi-Sankyo and Ono Pharma (H), Taiho Pharma (RF). The other authors indicated no financial relationships. (RF) Research funding; (H) Honoraria received.
